Hudson Bay Capital Management
MRSN

Hudson Bay Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Hudson Bay Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-38,494
Closed -$3.17M – 918
2023
Q2 		$3.17M Buy
38,494
+25,494
+196% +$3.73M 0.03% 409
2023
Q1 		$1.34M Buy
13,000
+2,000
+18% +$281K 0.01% 567
2022
Q4 		$1.61M Buy
11,000
+1,200
+12% +$203K 0.02% 633
2022
Q3 		$1.66M Sell
9,800
-6,200
-39% -$1.01M 0.02% 772
2022
Q2 		$1.85M Sell
16,000
-1,400
-8% -$132K 0.02% 824
2022
Q1 		$1.74M Buy
17,400
+5,800
+50% +$678K 0.02% 735
2021
Q4 		$1.8M Buy
11,600
+4,600
+66% +$895K 0.02% 710
2021
Q3 		$1.65M Buy
7,000
+4,200
+150% +$1.23M 0.02% 675
2021
Q2 		$951K Buy
+2,800
New +$1.06M 0.01% 746

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $50.9B AUM 42.89% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $849M AUM 470.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return